“…Some of the N‐heterocyclic containing EGFR inhibitor approved by the US FDA are shown in Figure 5 [44,59] . Moreover, N‐heterocyclic compounds exhibit different biological properties such as anti‐HIV, antidiabetic, herbicidal activity, anticancer activity, insecticidal agents, anti‐inflammatory, [60] antibacterial, [41b] antioxidant, [44,61] anticonvulsant, [58b,62] antiallergic, and enzyme inhibitors. These N‐heterocyclic rings also meet the fundamental pharmacophore which is a prerequisite requirement for any molecule to be an EGFR inhibitor.…”